在没有减少喷射小部分的患者中,经过透气管大动脉植入后的拉米普利尔:RASTAVI随机临床试验
Ignacio J Amat-Santos1,2, Diego López-Otero2,3, Luis Nombela-Franco4
1Cardiology Department Hospital Clínico Universitario de Valladolid Spain.
Journal of the American Heart Association
|September 18, 2024
概括
拉米普利在通过导管的大动脉植入后并没有显著减少主要不良事件,但在保留喷射分数的患者中降低了心力衰竭再入院率.
科学领域:
- 心脏病学 心脏病学
- 心血管外科心血管外科
- 药理学 药理学是指药理学的学科.
背景情况:
- 接受过导管大动脉植入 (TAVI) 的患者面临着心力衰竭,心律失常和死亡的持续风险.
- 列宁- ангиотензин系统抑制剂正在研究它们在TAVI后患者的潜在益处.
研究的目的:
- 调查拉米普利尔在改善TAVI后大动脉狭窄患者的治疗结果方面的疗效.
- 评估拉米普利尔对心脏病死亡率,心力衰竭再入院和中风的影响.
主要方法:
- 该PROBE试验是一项多中心研究,随机将186名TAVI后的患者分为拉米普里尔或标准治疗.
- 主要终点是心脏病死亡率,心力衰竭再入院和1年内中风的复合结果.
- 二级终点包括左心室重塑和通过心脏MRI评估的纤维化.
主要成果:
- 主要终点发生在10.6%的拉米普里尔组,而对照组为12% (P=0.776).
- 拉米普利显著降低了心力衰竭的再入院 (3.2%与10.9%,P=0.040),但心脏死亡率没有差异.
- 拉米普利改善了左心室重塑,与对照组相比,心室体积减少更大.
结论:
- 在TAVI后给出拉米普利尔的患者中,喷射分数保留的患者没有达到主要复合终点.
- 拉米普利在1年的随访中与心力衰竭再入院的显著减少有关.
- 拉米普里尔在TAVI后左心室重塑方面表现出好处.
更多相关视频
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.2K
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
2.8K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
159
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
159